Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS

2022 TYSABRI (Natalizumab) Report: A Recombinant Humanized IgG4 Monoclonal Antibody Produced in Murine Myeloma Cells - Drug Insight and Market Forecasts to 2032 Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "TYSABRI (Natalizumab), Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering."TYSABRI (Natalizumab),...

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data...

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...

First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been...